These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
424 related articles for article (PubMed ID: 22945774)
21. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes. Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722 [TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726 [TBL] [Abstract][Full Text] [Related]
23. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]. zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545 [TBL] [Abstract][Full Text] [Related]
24. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280 [TBL] [Abstract][Full Text] [Related]
25. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253 [TBL] [Abstract][Full Text] [Related]
26. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681 [TBL] [Abstract][Full Text] [Related]
27. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry]. Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543 [TBL] [Abstract][Full Text] [Related]
28. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. van der Velden VH; Cazzaniga G; Schrauder A; Hancock J; Bader P; Panzer-Grumayer ER; Flohr T; Sutton R; Cave H; Madsen HO; Cayuela JM; Trka J; Eckert C; Foroni L; Zur Stadt U; Beldjord K; Raff T; van der Schoot CE; van Dongen JJ; Leukemia; 2007 Apr; 21(4):604-11. PubMed ID: 17287850 [TBL] [Abstract][Full Text] [Related]
29. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols. Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436 [TBL] [Abstract][Full Text] [Related]
30. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517 [TBL] [Abstract][Full Text] [Related]
31. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Brüggemann M; van der Velden VH; Raff T; Droese J; Ritgen M; Pott C; Wijkhuijs AJ; Gökbuget N; Hoelzer D; van Wering ER; van Dongen JJ; Kneba M Leukemia; 2004 Apr; 18(4):709-19. PubMed ID: 14961040 [TBL] [Abstract][Full Text] [Related]
32. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study. Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R; Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877 [TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements. Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341 [TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Flohr T; Schrauder A; Cazzaniga G; Panzer-Grümayer R; van der Velden V; Fischer S; Stanulla M; Basso G; Niggli FK; Schäfer BW; Sutton R; Koehler R; Zimmermann M; Valsecchi MG; Gadner H; Masera G; Schrappe M; van Dongen JJ; Biondi A; Bartram CR; Leukemia; 2008 Apr; 22(4):771-82. PubMed ID: 18239620 [TBL] [Abstract][Full Text] [Related]
35. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease. Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313 [TBL] [Abstract][Full Text] [Related]
36. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043 [TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL). Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217 [TBL] [Abstract][Full Text] [Related]